UFP Technologies Q2 revenue beats estimates on the back of medtech segment

UFP Technologies

03/08/2026 21:27

Overview
Medical device contract manufacturer's Q2 revenue rose 15%, beating analyst expectations
Adjusted EPS for Q2 increased to $2.92 from $2.50 a year ago
Growth driven by MedTech segment and investments in Dominican Republic operations

Outlook
Company sees opportunities to grow with existing customers and new program launches
Company continues to invest in Dominican Republic operations to support growth initiatives

Result Drivers
MEDTECH SEGMENT GROWTH - Co said both top five customers and the rest of its MedTech business posted strong sales gains in Q2
DOMINICAN REPUBLIC INVESTMENTS - Co said ongoing investments in Dominican Republic operations are supporting customer-driven growth and expanding capacity
MARGIN PRESSURE IN U.S. - Co said investments in Dominican Republic are creating near-term mix and margin pressure within U.S. operations

Company press release: ID:nBw8nK1Mva

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$174 mln
$159.38 mln (4 Analysts)
Q2 Net Income
 
$20.90 mln
 
Q2 Operating Income
 
$28.10 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for UFP Technologies Inc is $324.50, about 27.4% above its July 31 closing price of $254.78
The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 19 three months ago

Reuters Recommended Reads
Aug 3 - Integer Holdings Q2 sales fall 2.6%; KKR to buy company for $5.7 billion
Aug 3 - ClearPoint Neuro Q2 revenue rises 18% but misses estimates
Aug 3 - GeneDx Q2 revenue beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)